219 stocks outperformed expectations, with the top 50 concentrated in the electronics, chemical, pharmaceutical and biological industries

"Pharmaceutical Network Industry Dynamics" With the third quarter of listed companies reported the official, benefiting from product prices, industry boom, the company's business beat the industry and other factors, the performance exceeded expectations has become one of the driving force behind the continued rise of individual stocks.
Securities Times Data Bao based on brokerage performance reviews and research reports, and excluding new shares listed this year, statistics of the first three quarters or third quarter performance exceeded expectations of a total of 219 stocks, and combined with the institutions to forecast the growth rate of individual stocks net profit indicators, released the performance of more than expected top 50.
industry, the top 50 companies are mainly concentrated in electronics, chemicals, pharmaceutical biology, automotive and other industries.
In the pharmaceutical and biological sector, there are no shortage of large-cap companies, such as vaccine leader Zhifei Bio, which achieved total operating income of RMB11.050 billion in the first three quarters of this year, up 44.14% YoY, and net profit attributable to shareholders of the parent company of RMB2,479 million, up 40.59% YoY.
this measure, the first three quarters of Zhifei Bio's total operating income and home-to-home net profit have exceeded the full year 2019, laying the foundation for the 2020 full-year earnings growth.
from a continuing point of view, medical care leading enterprises Zhende Medical, veterinary drug group enterprises Rip Bio and other pharmaceutical bio-stocks are also believed by brokerage institutions to continue to exceed expectations.
, in the first three quarters of 2020, Zhende Medical achieved operating income of RMB8,117 million, up 531.52% YoY, and net profit attributable to shareholders of listed companies was RMB2,098 million, up 2105.56 percent YoY.
addition to the good results, Zhende Medical's share price this year is also very good.
's total market value has risen from 3,045 million yuan at the end of 2019 to 14,529 million yuan at the end of September 2020, according to
Choice Financial Terminals.
the company's better-than-expected results, the share prices of listed companies also rose simultaneously.
219 companies that outperformed expectations rose an average of 72.41 per cent this year, compared with a 5.72 per cent gain in the Shanghai index over the same period, according to the Shanghai Composite Index.
58 companies, including Zhende Medical, Zhifei Bio and Haier Bio, have doubled their share prices over the year, led by pharmaceutical and biological companies.
the above-mentioned company's performance exceeded expectations can be seen, mainly related to the industry's high business climate, product prices and the company's business outperforming the industry and other factors.
, the majority of companies benefiting from better-than-expected results, such as Ophthalmology and High-Business Eyre Ophthalmology.
compared with the dismal half-yearly report, Eyre Eye reported double revenue and net profit growth in the third quarter.
revenue in the first three quarters of this year was RMB8,565 million, an increase of 10.78 percent over the same period, and net profit attributable to the parent company was RMB1.546 billion, an increase of 25.6 percent over the same period.
For the high growth in the third quarter, some analysts believe that the business operated by Eyre Ophthalmology has become rigid demand, the market base on the performance support role is obvious, the early impact of the outbreak, the outbreak of demand after the outbreak relief, but also let Eyre Ophthalmology performance showed a high growth trend after the previous low.
product price increases, for example, amino metformin pesticides, the leading pharmaceutical enterprises in Hunan Haili, the company's six major products prices have continued to rise in the past four years, the third quarter product prices rose more than expected, resulting in the company's better-than-expected performance.
In addition, in the company's business to win the industry, the industry through the listed companies three-quarter results combed found that the overall performance of listed companies is better than the industry level, which reflects the listed companies as the leader in the sub-sector, performance is higher than the industry average, industry concentration shows an upward trend.